The First Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, 510000, China.
The Second Clinical College, Heilongjiang University of Chinese Medicine, Harbin, 150000, China.
Sci Rep. 2024 Nov 11;14(1):27501. doi: 10.1038/s41598-024-78890-6.
Depression frequently comorbidities with cancer, adversely affecting survivors' quality of life. Liver dysfunction is also prevalent among cancer survivors. However, the association between these two conditions remains unclear. This study aimed to explore the relationship between depression and liver function biomarkers in US cancer survivors. A cross-sectional study was conducted utilizing data from the National Health and Nutrition Examination Survey (NHANES) 2005-2020. Cancer survivors were screened and depression was assessed using the Patient Health Questionnaire-9 (PHQ-9), and 18 liver function biomarkers were included. Survey-weighted generalized linear models with multiple covariables adjusted were employed to examine the associations between depression and liver function biomarkers. A total of 4118 cancer survivors were included, representing a weighted population of 21 501 237. After adjusted with age, gender, race, marital status, education level, family income-to-poverty ratio, and number of cancer types, 8 biomarkers demonstrated positive correlations with depression in cancer survivors, included alanine aminotransferase (ALT, OR = 1.007, 95% CI: 1.000 to 1.013), alkaline phosphatase (ALP, 1.006 [1.002, 1.010]), gamma glutamyl transferase (GGT, 1.004 [1.001, 1.007]), lactate dehydrogenase (LDH, 1.004 [1.000, 1.009]), total protein (TP, 1.040 [1.009, 1.072]), globulin (GLB, 1.060 [1.030, 1.091]), total cholesterol (TC) to high-density lipoprotein cholesterol (HDL-C) ratio (1.162 [1.050, 1.286]), and low-density lipoprotein cholesterol (LDL-C) to HDL-C ratio (1.243 [1.012, 1.526]); while 4 other biomarkers exhibited negative correlations, included HDL-C (0.988 [0.980, 0.997]), total bilirubin (TBi, 0.501 [0.284, 0.883]), aspartate aminotransferase (AST) to ALT ratio (0.588 [0.351, 0.986]), albumin (ALB) to GLB ratio (0.384 [0.229, 0.642]). Following sensitivity analysis, 5 biomarkers included LDH, HDL-C, TBi, AST/ALT and LDL-C/HDL-C lost their statistical significance for the association. This study identified certain associations between 7 liver function biomarkers and depression in US cancer survivors. Further research, particularly prospective longitudinal studies, is warranted to elucidate the causal relationships and explore the potential of improving liver function for the management of depression in cancer patients.
抑郁症常与癌症并存,严重影响癌症幸存者的生活质量。肝功能障碍在癌症幸存者中也很常见。然而,这两种情况之间的关联仍不清楚。本研究旨在探讨美国癌症幸存者中抑郁与肝功能生物标志物之间的关系。本研究采用 2005-2020 年国家健康和营养调查(NHANES)的数据进行了一项横断面研究。通过使用患者健康问卷-9(PHQ-9)对癌症幸存者进行筛查和评估抑郁,共纳入了 18 种肝功能生物标志物。采用多变量调整的加权广义线性模型来检验抑郁与肝功能生物标志物之间的关系。共纳入 4118 例癌症幸存者,代表了 21501237 例加权人群。在调整了年龄、性别、种族、婚姻状况、教育水平、家庭收入与贫困比以及癌症类型数量后,在癌症幸存者中,有 8 种生物标志物与抑郁呈正相关,包括丙氨酸氨基转移酶(ALT,OR=1.007,95%CI:1.000-1.013)、碱性磷酸酶(ALP,1.006[1.002-1.010])、γ-谷氨酰转移酶(GGT,1.004[1.001-1.007])、乳酸脱氢酶(LDH,1.004[1.000-1.009])、总蛋白(TP,1.040[1.009-1.072])、球蛋白(GLB,1.060[1.030-1.091])、总胆固醇(TC)与高密度脂蛋白胆固醇(HDL-C)比值(1.162[1.050-1.286])和低密度脂蛋白胆固醇(LDL-C)与高密度脂蛋白胆固醇(HDL-C)比值(1.243[1.012-1.526]);而另外 4 种生物标志物则呈负相关,包括高密度脂蛋白胆固醇(HDL-C,0.988[0.980-0.997])、总胆红素(TBi,0.501[0.284-0.883])、天冬氨酸氨基转移酶(AST)与丙氨酸氨基转移酶(ALT)比值(0.588[0.351-0.986])和白蛋白(ALB)与球蛋白(GLB)比值(0.384[0.229-0.642])。在敏感性分析后,包括乳酸脱氢酶(LDH)、高密度脂蛋白胆固醇(HDL-C)、总胆红素(TBi)、AST/ALT 和 LDL-C/HDL-C 在内的 5 种生物标志物与抑郁之间的关联失去了统计学意义。本研究在美国癌症幸存者中发现了某些肝功能生物标志物与抑郁之间的关联。需要进一步的研究,特别是前瞻性纵向研究,以阐明因果关系,并探索改善肝功能对癌症患者抑郁管理的潜力。